{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:07:28Z","timestamp":1788865648864,"version":"build-2803163510"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Heart failure arising in cardiovascular-kidney-metabolic (CKM) syndrome, hereafter referred to as CKM-related heart failure (CKM-HF), is increasingly understood as the cardiac expression of multisystem endocrine and metabolic stress rather than as an isolated myocardial disorder. In this narrative review, we examine how kidney, bone, adipose tissue, gut, pancreas, vasculature, and myocardium communicate through maladaptive hormonal and metabolic signals, with particular emphasis on heart failure with preserved ejection fraction (HFpEF). We position the fibroblast growth factor 23 (FGF23)-Klotho axis as a candidate organizing framework for mineral endocrine stress in diabetic kidney disease and chronic kidney disease. Human observational studies associate higher circulating FGF23 and altered Klotho biology with adverse cardiovascular phenotypes, whereas preclinical studies provide mechanistic plausibility for links to cardiac hypertrophy and fibrosis. However, current evidence does not establish that elevated FGF23 directly causes cardiac remodeling in humans. We examine insulin resistance, adipose dysfunction, RAAS activation, anemia, and gut-derived metabolites selectively as modifiers, competing pathways, or confounders that shape the interpretation of FGF23-Klotho biology in CKM-related heart failure. Established cardiometabolic therapies are discussed according to their proven clinical effects and as modifiers of the context in which FGF23 and soluble Klotho are interpreted; their efficacy is not considered evidence of FGF23-Klotho pathway engagement or mediation. An FGF23-Klotho-centered CKM-HF framework may support research phenotyping, prospective biomarker validation, and mechanism-based trial design. However, the proposed phenotype remains unvalidated, circulating FGF23 and soluble Klotho are not established for routine clinical use, and their incremental value beyond conventional kidney, mineral, cardiac, and imaging markers remains unknown.<\/jats:p>","DOI":"10.3389\/fendo.2026.1933732","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:14:20Z","timestamp":1788862460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Dan","family":"Sun","sequence":"first","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjia","family":"Wang","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Shen","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxu","family":"Meng","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabin","family":"Zhou","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","article-title":"2022 aha\/acc\/hfsa guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 esc guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 esc guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: A review","volume":"329","author":"Redfield","year":"2024","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ejhf.1741","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Pieske","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction","volume":"56","author":"Borlaug","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41569-023-00903-0","article-title":"FGF23 and klotho at the intersection of kidney and cardiovascular disease","volume":"21","author":"Edmonston","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/jme-20-0178","article-title":"FGF23 signalling and physiology","volume":"66","author":"Ho","year":"2021","journal-title":"J Mol Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/jci46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1059179","article-title":"Direct and indirect effects of fibroblast growth factor 23 on the heart","volume":"14","author":"Nakano","year":"2023","journal-title":"Front Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/cir.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.124.071079","article-title":"Albuminuria in cardiovascular, kidney, and metabolic disorders: A state-of-the-art review","volume":"151","author":"Claudel","year":"2025","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.117.008334","article-title":"Fibroblast growth factor-23 and heart failure with reduced versus preserved ejection fraction: MESA","volume":"7","author":"Almahmoud","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.024952","article-title":"Fibroblast growth factor 23 and risk of new onset heart failure with preserved or reduced ejection fraction: The PREVEND study","volume":"11","author":"Binnenmars","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100723","article-title":"Fibroblast growth factor 23 and risk of heart failure subtype: The CRIC (Chronic Renal Insufficiency Cohort) study","volume":"5","author":"Leidner","year":"2023","journal-title":"Kidney Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder guideline update: What's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"B40","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.117.311586","article-title":"Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2337\/db15-0627","article-title":"Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes","volume":"65","author":"Levelt","year":"2016","journal-title":"Diabetes"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: A randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/circulationaha.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the mouse klotho gene leads to a syndrome resembling ageing","volume":"390","author":"Kuro-o","year":"1997","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.c500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J Biol Chem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/jci61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals","volume":"60","author":"Ix","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/s41598-017-02068-6","article-title":"FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible","volume":"7","author":"Grabner","year":"2017","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/jci19081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2009121311","article-title":"Klotho deficiency causes vascular calcification in chronic kidney disease","volume":"22","author":"Hu","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201303716","article-title":"FGF23 regulates renal sodium handling and blood pressure","volume":"6","author":"Andrukhova","year":"2014","journal-title":"EMBO Mol Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.33594\/000000797","article-title":"Regulation of alphaKlotho","volume":"59","author":"Vogt","year":"2025","journal-title":"Cell Physiol Biochem"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.125.325516","article-title":"Gut-heart axis: the role of gut microbiota and metabolites in heart failure","volume":"136","author":"Snelson","year":"2025","journal-title":"Circ Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2020.08.007","article-title":"TMAO: how gut microbiota contributes to heart failure","volume":"228","author":"Zhang","year":"2021","journal-title":"Transl Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116567","article-title":"Role of the microbiota-gut-heart axis between bile acids and cardiovascular disease","volume":"174","author":"Zhang","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1109400","article-title":"Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk","volume":"368","author":"Tang","year":"2013","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.617","article-title":"Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure","volume":"64","author":"Tang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.r900007-jlr200","article-title":"Bile acids as regulatory molecules","volume":"50","author":"Hylemon","year":"2009","journal-title":"J Lipid Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.115.002314","article-title":"Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure","volume":"9","author":"Organ","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstrom","year":"2016","journal-title":"Cell Metab"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/nejmoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"B99","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.cir.0000112582.16683.ea","article-title":"Impact of obesity on plasma natriuretic peptide levels","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the european association of cardiovascular imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2020040411","article-title":"A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD)","volume":"31","author":"Toussaint","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4807","article-title":"Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial","volume":"325","author":"Ogata","year":"2021","journal-title":"JAMA"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.0139","article-title":"Association of fibroblast growth factor 23 with risk of incident coronary heart disease in community-living adults","volume":"3","author":"Panwar","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1053\/j.ajkd.2020.11.026","article-title":"CKD progression and mortality among men and women: A nationwide study in Sweden","volume":"78","author":"Swartling","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.122.062832","article-title":"Sex differences in characteristics, outcomes, and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER","volume":"147","author":"Wang","year":"2023","journal-title":"Circulation"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1933732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:14:22Z","timestamp":1788862462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1933732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":107,"alternative-id":["10.3389\/fendo.2026.1933732"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1933732","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1933732"}}